MXPA04002147A - Composiciones y metodos para inducir celulas dendriticas monociticas y celulas t para respuesta th-1. - Google Patents

Composiciones y metodos para inducir celulas dendriticas monociticas y celulas t para respuesta th-1.

Info

Publication number
MXPA04002147A
MXPA04002147A MXPA04002147A MXPA04002147A MXPA04002147A MX PA04002147 A MXPA04002147 A MX PA04002147A MX PA04002147 A MXPA04002147 A MX PA04002147A MX PA04002147 A MXPA04002147 A MX PA04002147A MX PA04002147 A MXPA04002147 A MX PA04002147A
Authority
MX
Mexico
Prior art keywords
cells
methods
response
compositions
type
Prior art date
Application number
MXPA04002147A
Other languages
English (en)
Spanish (es)
Inventor
L Bosch Marnix
Original Assignee
Northwest Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwest Biotherapeutics Inc filed Critical Northwest Biotherapeutics Inc
Publication of MXPA04002147A publication Critical patent/MXPA04002147A/es

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/15Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5428IL-10
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5434IL-12
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/555Interferons [IFN]
    • C07K14/57IFN-gamma
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0639Dendritic cells, e.g. Langherhans cells in the epidermis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5154Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5158Antigen-pulsed cells, e.g. T-cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55522Cytokines; Lymphokines; Interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588Adjuvants of undefined constitution
    • A61K2039/55594Adjuvants of undefined constitution from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/70Undefined extracts
    • C12N2500/72Undefined extracts from bacteria
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/24Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
MXPA04002147A 2001-09-06 2002-09-06 Composiciones y metodos para inducir celulas dendriticas monociticas y celulas t para respuesta th-1. MXPA04002147A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31759201P 2001-09-06 2001-09-06
PCT/US2002/028620 WO2003022215A2 (en) 2001-09-06 2002-09-06 Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response

Publications (1)

Publication Number Publication Date
MXPA04002147A true MXPA04002147A (es) 2005-03-07

Family

ID=32654226

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04002147A MXPA04002147A (es) 2001-09-06 2002-09-06 Composiciones y metodos para inducir celulas dendriticas monociticas y celulas t para respuesta th-1.

Country Status (17)

Country Link
US (2) US20050059151A1 (enExample)
EP (3) EP2322603B1 (enExample)
JP (3) JP2005505270A (enExample)
KR (3) KR20110081341A (enExample)
CN (2) CN1636229B (enExample)
AU (1) AU2008221592B2 (enExample)
BR (1) BRPI0212545B8 (enExample)
CA (1) CA2459713C (enExample)
DK (2) DK1441591T3 (enExample)
ES (2) ES2598109T3 (enExample)
IL (3) IL160720A0 (enExample)
MX (1) MXPA04002147A (enExample)
NO (2) NO338147B1 (enExample)
NZ (1) NZ531530A (enExample)
PL (1) PL372098A1 (enExample)
PT (2) PT2322603T (enExample)
WO (1) WO2003022215A2 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT412145B (de) * 2002-09-13 2004-10-25 Forsch Krebskranke Kinder Verfahren zur herstellung eines zellulären immuntherapeutikums auf basis von il-12-freisetzenden dendritischen zellen
US20040057935A1 (en) * 2002-09-20 2004-03-25 Cedars-Sinai Medical Center Intratumoral delivery of dendritic cells
ES2354944T3 (es) * 2002-12-06 2011-03-21 Northwest Biotherapeutics, Inc. Administración de células dendríticas maduradas parcialmente in vitro para el tratamiento de tumores.
KR101201875B1 (ko) * 2003-02-27 2012-11-15 노쓰웨스트 바이오써라퓨틱스, 인크. 부가의 사이토킨의 부재하에 gm-csf를 사용한 단핵구수지상 전구체 세포로부터의 수지상 세포 생성방법
EP1484064A1 (en) 2003-06-04 2004-12-08 Gesellschaft für Biotechnologische Forschung Therapeutical composition containing dentritic cells and use thereof
JP2007507543A (ja) * 2003-10-06 2007-03-29 セダーズ−シナイ メディカル センター 樹状細胞治療によって誘導されるt細胞アネルギーを予防するためのcox−2インヒビターの使用
EP1676132B1 (en) * 2003-10-21 2014-01-22 Cedars-Sinai Medical Center Combination of chemotherapy and administration of glioma-antigen-pulsed dendritic cells in the treatment of glioma
KR101279748B1 (ko) * 2003-11-04 2013-07-04 가부시키가이샤 디나벡크 겐큐쇼 유전자 도입된 수상세포의 제조방법
AU2005257107A1 (en) 2004-06-24 2006-01-05 Dnavec Research Inc. Anticancer agent containing dendritic cell having RNA virus transferred thereinto
EP1957634A4 (en) * 2005-12-08 2010-01-27 Northwest Biotherapeutics Inc COMPOSITIONS AND METHODS OF INDUCING THE ACTIVATION OF UNREFERENCE MONOCYTIC DENDRITE CELLS
EP1840206A1 (en) * 2006-03-28 2007-10-03 Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh Compositions for the preparation of mature dendritic cells
CA2700573C (en) 2006-09-26 2016-11-22 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
US8871211B2 (en) 2006-09-28 2014-10-28 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
PL2328923T3 (pl) * 2008-09-02 2016-06-30 Cedars Sinai Medical Center Epitopy CD133
US8383768B2 (en) * 2009-05-07 2013-02-26 Immunocellular Therapeutics, Ltd. CD133 epitopes
CA2863653A1 (en) * 2012-02-02 2013-08-08 California Stem Cell, Inc. Pluripotent germ layer origin antigen presenting cancer vaccine
EP2857498B1 (en) * 2012-05-31 2018-04-25 JW Creagene Inc. Composition for maturing dendritic cells, and method for preparing antigen-specific dendritic cells using same
US20140065173A1 (en) * 2012-09-06 2014-03-06 Orbis Health Solutions Llc Tumor lysate loaded particles
AU2020203845C1 (en) * 2012-09-06 2022-08-11 Orbis Health Solutions, Llc Tumor lysate loaded particles
US10188672B2 (en) 2012-12-12 2019-01-29 Orbis Health Solutions Llc Compositions and methods for tissue regeneration
ES2662333T3 (es) 2013-02-14 2018-04-06 Immunocellular Therapeutics Ltd. Vacunas contra el cáncer y métodos de vacunación
CN112891522A (zh) * 2013-09-05 2021-06-04 奥比思健康解决方案有限责任公司 装载了肿瘤裂解物的微粒
JP6797022B2 (ja) 2014-03-05 2020-12-09 オービス ヘルス ソリューションズ エルエルシー 酵母細胞壁粒子を用いたワクチン送達系
US11669090B2 (en) 2014-05-20 2023-06-06 State Farm Mutual Automobile Insurance Company Autonomous vehicle operation feature monitoring and evaluation of effectiveness
US9972054B1 (en) 2014-05-20 2018-05-15 State Farm Mutual Automobile Insurance Company Accident fault determination for autonomous vehicles
US10599155B1 (en) 2014-05-20 2020-03-24 State Farm Mutual Automobile Insurance Company Autonomous vehicle operation feature monitoring and evaluation of effectiveness
US10373259B1 (en) 2014-05-20 2019-08-06 State Farm Mutual Automobile Insurance Company Fully autonomous vehicle insurance pricing
US10185997B1 (en) * 2014-05-20 2019-01-22 State Farm Mutual Automobile Insurance Company Accident fault determination for autonomous vehicles
US10832327B1 (en) 2014-07-21 2020-11-10 State Farm Mutual Automobile Insurance Company Methods of providing insurance savings based upon telematics and driving behavior identification
US10431018B1 (en) 2014-11-13 2019-10-01 State Farm Mutual Automobile Insurance Company Autonomous vehicle operating status assessment
EP3317402B1 (en) 2015-06-30 2024-02-14 Universidade Nova de Lisboa A viable cell population, method for production and uses thereof
EP3317403B1 (en) * 2015-06-30 2025-03-05 NorthWest Biotherapeutics, Inc. Optimally activated dendritic cells that induce an improved or increased anti-tumor immune response
US9868394B1 (en) 2015-08-28 2018-01-16 State Farm Mutual Automobile Insurance Company Vehicular warnings based upon pedestrian or cyclist presence
US11719545B2 (en) 2016-01-22 2023-08-08 Hyundai Motor Company Autonomous vehicle component damage and salvage assessment
US11441916B1 (en) 2016-01-22 2022-09-13 State Farm Mutual Automobile Insurance Company Autonomous vehicle trip routing
US10395332B1 (en) 2016-01-22 2019-08-27 State Farm Mutual Automobile Insurance Company Coordinated autonomous vehicle automatic area scanning
US10818105B1 (en) 2016-01-22 2020-10-27 State Farm Mutual Automobile Insurance Company Sensor malfunction detection
US11242051B1 (en) 2016-01-22 2022-02-08 State Farm Mutual Automobile Insurance Company Autonomous vehicle action communications
US10134278B1 (en) 2016-01-22 2018-11-20 State Farm Mutual Automobile Insurance Company Autonomous vehicle application
US10324463B1 (en) 2016-01-22 2019-06-18 State Farm Mutual Automobile Insurance Company Autonomous vehicle operation adjustment based upon route
KR102038114B1 (ko) * 2016-02-26 2019-10-30 주식회사 엘지화학 광학 점착제용 (메타)아크릴레이트기 함유 벤조페논의 제조방법 및 광학 점착제 조성물
WO2018160666A1 (en) * 2017-02-28 2018-09-07 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Short-term activated dc1s and methods for their production and use
WO2019183924A1 (en) * 2018-03-30 2019-10-03 Syz Cell Therapy Co. Improved multiple antigen specific cell therapy methods
BR112022006743A2 (pt) * 2019-10-07 2022-08-30 Northwest Biotherapeutics Inc Composições e métodos in vitro para potencializar a ativação de células dendríticas e células t e para induzir uma resposta imunológica de th-1

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162504A (en) * 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US5366866A (en) * 1991-07-25 1994-11-22 Duke University Method of diagnosing ovarian and endometrial cancer with monoclonal antibodies OXA and OXB
US5227471A (en) * 1992-01-30 1993-07-13 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Monoclonal antibody PD41 that binds to a prostate mucin antigen that is expressed in human prostatic carcinoma
US5788963A (en) 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
CA2232865A1 (en) * 1995-10-04 1997-04-10 Immunex Corporation The use of flt3 ligand to generate dendritic cells
US7659119B2 (en) * 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
EP0922758B1 (en) * 1997-10-27 2009-04-15 Rockefeller University Methods and compositions for obtaining mature dendritic cells
JP2000143534A (ja) * 1998-11-13 2000-05-23 Asahi Chem Ind Co Ltd 樹状細胞ワクチン及びその製造方法
JP2000279181A (ja) * 1999-04-01 2000-10-10 Japan Science & Technology Corp ヒト樹状細胞の発現遺伝子群
EP1254953A4 (en) * 1999-12-28 2004-06-02 Toyoshima Kumao Maturity-triggering agent for immature dendritic cells
US6247378B1 (en) * 2000-01-06 2001-06-19 Deere & Company Operator control device for an infinitely variable transmission
US20030175247A1 (en) * 2000-05-12 2003-09-18 Michael Salgaller Method to increase class I presentation of exogenous antigens by human dendritic cells
ATE317428T1 (de) * 2001-01-15 2006-02-15 Idm Immuno Designed Molecules Verfahren zur herstellung von submikropartikel- suspensionen pharmazeutischer substanzen
AU2002326463A1 (en) * 2001-07-25 2003-02-17 Northwest Biotherapeutics, Inc. Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors

Also Published As

Publication number Publication date
AU2008221592B2 (en) 2012-12-20
AU2008221592A1 (en) 2008-10-16
CN1636229A (zh) 2005-07-06
BR0212545A (pt) 2005-01-18
KR20110081341A (ko) 2011-07-13
NO20151562A1 (no) 2015-11-16
CN102973928B (zh) 2019-03-15
IL219266A0 (en) 2012-06-28
US20080254064A1 (en) 2008-10-16
EP1441591A2 (en) 2004-08-04
JP2011188872A (ja) 2011-09-29
NZ531530A (en) 2007-01-26
IL160720A0 (en) 2004-08-31
PT2322603T (pt) 2020-01-21
HK1079989A1 (en) 2006-04-21
EP3653055A1 (en) 2020-05-20
BRPI0212545A8 (pt) 2019-10-15
BRPI0212545B8 (pt) 2021-05-25
IL160720A (en) 2012-05-31
KR101803702B1 (ko) 2017-12-01
DK2322603T3 (da) 2020-01-27
NO20040965L (no) 2004-04-23
WO2003022215A3 (en) 2003-11-13
CA2459713A1 (en) 2003-03-20
ES2598109T3 (es) 2017-01-25
BRPI0212545B1 (pt) 2019-12-03
JP2005505270A (ja) 2005-02-24
CN1636229B (zh) 2012-12-19
WO2003022215A2 (en) 2003-03-20
CA2459713C (en) 2015-08-18
EP2322603B1 (en) 2019-10-16
JP5777956B2 (ja) 2015-09-16
EP1441591B1 (en) 2016-06-29
KR20050027163A (ko) 2005-03-17
PT1441591T (pt) 2016-10-06
EP2322603A1 (en) 2011-05-18
PL372098A1 (en) 2005-07-11
DK1441591T3 (en) 2017-05-22
KR20140116544A (ko) 2014-10-02
NO338147B1 (no) 2016-08-01
CN102973928A (zh) 2013-03-20
EP1441591A4 (en) 2006-06-07
JP2015107133A (ja) 2015-06-11
ES2766299T3 (es) 2020-06-12
US20050059151A1 (en) 2005-03-17
IL219266A (en) 2014-02-27
JP6114768B2 (ja) 2017-04-12

Similar Documents

Publication Publication Date Title
MXPA04002147A (es) Composiciones y metodos para inducir celulas dendriticas monociticas y celulas t para respuesta th-1.
AU3877500A (en) Methods for preparing 3-aryloxy-3-arylpropylamines and intermediates thereof
IL166309A0 (en) Preparation of 1h-imidazoÄ4,5-cÜquinolin-4-amines via 1h-imidazoÄ4,5-cÜquinolin-4-phthalimide intermediates
BG104511A (en) Spheroids, preparation method and pharmaceutical compositions
EP2722387A3 (en) Definitive endoderm
NZ532665A (en) Neisseria meningitidis antigens and compositions
CA2396250A1 (en) Mutant apre promoter
YU27403A (sh) Postupak za pripremanje preparata u obliku praha
MXPA04011071A (es) Analisis de calidad para celulas que presentan antigenos.
EP1288931A3 (en) Optical recording article
JO2369B1 (en) New cyclohexyl sulfonate
IL151678A (en) Method for producing asymmetrical 4,6-bis (aryloxy) pyrimidine derivatives
DK0516647T3 (da) Polypeptider, som er involveret i biosyntesen af cobalaminer og/eller cobamider, DNA-sekvenser, som koder for disse polypep
AU2003227595A1 (en) Foam control agents
AU5334301A (en) Human ovarian mesothelial cells and methods of isolation and uses thereof
AU4925200A (en) Oral composition containing perlite
EP1613606A4 (en) PROCESS FOR PREPARING 2,3,5,6-SUBSTITUTED 3H-PYRIMIDIN-4-ONES
AU2002222695A1 (en) Novel 4'-demethyl-4'-o-substituted-1-deoxypodophyllotoxin derivative and geometric isomer thereof, process for the preparation thereof and anti-cancer composition comprising the same
MY130958A (en) Compositions comprising higher diamondoids and processes for their separation
UA66859C2 (uk) Спосіб стереохімічно контрольованого одержання ізомерно чистих високозаміщених азациклічних сполук
MXPA02011064A (es) Proceso para la preparacion de 2,3-pentandiona.
WO2002062758A1 (en) Indoline derivative and process for producing the same
AU2003238198A1 (en) Method for producing 4,6-dichloro-5-fluoropyrimidine
TW200621712A (en) (+)-6-cyano-3-n-methylamino-1,2,3,4-tetrahydrocarbazole and salts and solvates thereof
EP1413233A3 (de) Wäschebügel, insbesondere für String-Tanga

Legal Events

Date Code Title Description
FG Grant or registration